Radiopharm Theranostics Ltd (RADX) Other Operating Expenses (2023 - 2025)

Radiopharm Theranostics (RADX) has reported Other Operating Expenses for 3 consecutive years, with -$4.1 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Other Operating Expenses rose 54.07% year-over-year to -$4.1 million in Q2 2025; TTM through Jun 2026 was -$15.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$4.1 million, up 54.07% from the prior year.
• Other Operating Expenses was -$4.1 million for Q2 2025 at Radiopharm Theranostics, up from -$8.9 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at -$2.7 million in Q2 2023 and troughed at -$8.9 million in Q2 2024.
• A 3-year average of -$5.2 million and a median of -$4.1 million in 2025 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses slumped 230.08% in 2024 and surged 54.07% in 2025, its largest moves.
• Over 3 years, Other Operating Expenses stood at -$2.7 million in 2023, then tumbled by 230.08% to -$8.9 million in 2024, then surged by 54.07% to -$4.1 million in 2025.
• The last three Other Operating Expenses figures came in at -$4.1 million (Q2 2025), -$8.9 million (Q2 2024), and -$2.7 million (Q2 2023), per Business Quant data.